Increased levels of serum leptin in the early stages of psychosis

Martorell, Lourdes; Muntané, Gerard; Porta-López, Sara; Moreno, I. Huguet; Ortega, Laura; Montalvo, Itziar; Sánchez‐Gistau, Vanessa; Monseny, Rosa; Labad, Javier; Vilella, Elisabet

doi:10.1016/j.jpsychires.2019.01.006

Cited by 21 publications

(18 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Martorell and colleagues, in their study published in 2019, detected increased leptin levels in the early stages of psychosis [69]. They compared 39 first-episode psychosis (FEP) patients, 32 psychotic patients in the critical period and 21 healthy controls [69]. They also found significant correlations between leptin levels and anthropometric, lipid, hormone, and cytokine parameters [69].…”

Section: Leptin and Psychiatric Illnessesmentioning

confidence: 99%

“…Indeed, two recent meta-analyses showed an increase in leptin for schizophrenia patients compared to controls, with more marked elevation during decompensations episodes [67,68]. Martorell and colleagues, in their study published in 2019, detected increased leptin levels in the early stages of psychosis [69]. They compared 39 first-episode psychosis (FEP) patients, 32 psychotic patients in the critical period and 21 healthy controls [69].…”

Section: Leptin and Psychiatric Illnessesmentioning

confidence: 99%

“…They compared 39 first-episode psychosis (FEP) patients, 32 psychotic patients in the critical period and 21 healthy controls [69]. They also found significant correlations between leptin levels and anthropometric, lipid, hormone, and cytokine parameters [69]. In a metaanalysis including 1674 patients and 2033 controls, Stubbs and collaborators reported increased leptin levels in patients with mean illness duration of 9.3 years [67].…”

Section: Leptin and Psychiatric Illnessesmentioning

confidence: 99%

See 2 more Smart Citations

Leptin and psychiatric illnesses: does leptin play a role in antipsychotic-induced weight gain?

et al. 2020

View full text Add to dashboard Cite

Antipsychotic-induced weight gain is the most prevalent somatic adverse event occurring in patients treated by antipsychotics, especially atypical antipsychotics. It is of particular interest because of its repercussion on cardiovascular morbidity and mortality especially now that the use of second-generation antipsychotics has been extended to other mental health illnesses such as bipolar disorders and major depressive disorder. The mechanism underlying antipsychotics-induced weight gain is still poorly understood despite a significant amount of work on the topic. Recently, there has been an ongoing debate of tremendous research interest on the relationship between antipsychotic-induced weight gain and body weight regulatory hormones such as leptin. Given that, researchers have brought to light the question of leptin's role in antipsychotic-induced weight gain. Here we summarize and discuss the existing evidence on the link between leptin and weight gain related to antipsychotic drugs, especially atypical antipsychotics.

show abstract

Section: Leptin and Psychiatric Illnessesmentioning

confidence: 99%

Section: Leptin and Psychiatric Illnessesmentioning

confidence: 99%

Section: Leptin and Psychiatric Illnessesmentioning

confidence: 99%

See 1 more Smart Citation

Leptin and psychiatric illnesses: does leptin play a role in antipsychotic-induced weight gain?

et al. 2020

View full text Add to dashboard Cite

show abstract

“…(2019) исследовали содержание лептина в крови у больных с первым эпизодом шизофрении и у лиц, имеющих риск развития психоза. В обеих группах концентрация лептина превышала таковую у представителей группы контроля [23]. При этом, по данным R. Balõtšev и соавт.…”

Section: Psychiatryunclassified

The Role of Adipokines in the Development of Metabolic Disorders in Schizophrenic Patients

Озорнин¹,

Govorin²,

Sakharov³

2020

View full text Add to dashboard Cite

Цель обзора: систематизация научных данных о влиянии адипокинов на формирование метаболического синдрома у больных шизофренией. Основные положения. Лептин и адипонектин участвуют в регуляции метаболических процессов организма, поэтому изменение их концентраций имеет значение для формирования метаболических расстройств. Многочисленными исследованиями установлено, что у больных шизофренией на фоне психофармакотерапии увеличивается содержание лептина и снижается концентрация адипонектина, причем более выраженные изменения происходят при терапии антипсихотиками второго поколения (клозапином, оланзапином, кветиапином). Установлены корреляции между изменениями содержания лептина и адипонектина и некоторыми метаболическими нарушениями. При этом если лептин и адипонектин изучены глубоко и разносторонне, то роль других адипокинов в формировании компонентов метаболического синдрома при шизофрении требует дальнейшего уточнения, в том числе в условиях психофармакотерапии и с учетом генетических особенностей пациентов. Заключение. Установление закономерностей изменения содержания адипокинов у больных шизофренией при нейролептической терапии с учетом их генетических особенностей позволит производить индивидуальное прогнозирование возникновения метаболического синдрома, что, несомненно, положительно отразится на их соматическом состоянии и качестве жизни. Ключевые слова: адипокины, шизофрения, нейролептики, метаболический синдром.

show abstract

“…5-HT1A, 5-HT2A and 5-HT2C), all of which have a role in AiWG (Amato, 2015;Buckley, 2007;Rasmussen et al, 2014). Of note, not only medication but also schizophrenia itself have been linked to metabolic features, such as levels of insulinrelated peptides (Guest et al, 2010), insulin resistance (Pillinger et al, 2017;Tomasik et al, 2019), HbA1c (Cao et al, 2017) and leptin resistance (Martorell et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

A new genetic locus for antipsychotic-induced weight gain: A genome-wide study of first-episode psychosis patients using amisulpride (from the OPTiMiSE cohort)

et al. 2020

View full text Add to dashboard Cite

Background: Antipsychotic-induced weight gain is a common and debilitating side effect of antipsychotics. Although genome-wide association studies of antipsychotic-induced weight gain have been performed, few genome-wide loci have been discovered. Moreover, these genome-wide association studies have included a wide variety of antipsychotic compounds. Aims: We aim to gain more insight in the genomic loci affecting antipsychotic-induced weight gain. Given the variable pharmacological properties of antipsychotics, we hypothesized that targeting a single antipsychotic compound would provide new clues about genomic loci affecting antipsychoticinduced weight gain. Methods: All subjects included for this genome-wide association study (n=339) were first-episode schizophrenia spectrum disorder patients treated with amisulpride and were minimally medicated (defined as antipsychotic use <2 weeks in the previous year and/or <6 weeks lifetime). Weight gain was defined as the increase in body mass index from before until approximately 1 month after amisulpride treatment. Results: Our genome-wide association analyses for antipsychotic-induced weight gain yielded one genome-wide significant hit (rs78310016; β=1.05; p=3.66 × 10 -08 ; n=206) in a locus not previously associated with antipsychotic-induced weight gain or body mass index. Minor allele carriers had an odds ratio of 3.98 (p=1.0 × 10 −03 ) for clinically meaningful antipsychotic-induced weight gain (⩾7% of baseline weight). In silico analysis elucidated a chromatin interaction with 3-Hydroxy-3-Methylglutaryl-CoA Synthase 1. In an attempt to replicate single-nucleotide polymorphisms previously associated with antipsychotic-induced weight gain, we found none were associated with amisulpride-induced weight gain. Conclusion: Our findings suggest the involvement of rs78310016 and possibly 3-Hydroxy-3-Methylglutaryl-CoA Synthase 1 in antipsychotic-induced weight gain. In line with the unique binding profile of this atypical antipsychotic, our findings furthermore hint that biological mechanisms underlying amisulpride-induced weight gain differ from antipsychotic-induced weight gain by other atypical antipsychotics.

show abstract

Increased levels of serum leptin in the early stages of psychosis

Cited by 21 publications

References 37 publications

Leptin and psychiatric illnesses: does leptin play a role in antipsychotic-induced weight gain?

Leptin and psychiatric illnesses: does leptin play a role in antipsychotic-induced weight gain?

The Role of Adipokines in the Development of Metabolic Disorders in Schizophrenic Patients

A new genetic locus for antipsychotic-induced weight gain: A genome-wide study of first-episode psychosis patients using amisulpride (from the OPTiMiSE cohort)

Contact Info

Product

Resources

About